The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | CAR-NK and CAR-T for MCL
Michael L. Wang, MD, MD Anderson Cancer Center, Houston, TX, shares an update on chimeric antigen receptor natural killer cell (CAR-NK) therapy, highlighting promising activity observed in B-cell lymphomas including B-cell acute lymphoblastic leukemia (B-ALL). Prof. Wang also gives an overview of the CAR T-cell therapies currently under investigation for mantle cell lymphoma (MCL), highlighting the approval of brexucabtagene autoleucel for relapsed/refractory MCL. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
